Compare · IPEX vs NVS
IPEX vs NVS
Side-by-side comparison of Inflection Point Acquisition Corp. V (IPEX) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IPEX and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS carries a market cap of $293.23B.
- Over the past year, IPEX is up 4.1% and NVS is up 30.4% - NVS leads by 26.3 points.
- IPEX has been more active in the news (3 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 0 for IPEX).
- Company
- Inflection Point Acquisition Corp. V
- Novartis AG
- Price
- $10.55+0.00%
- $153.68-1.61%
- Market cap
- -
- $293.23B
- 1M return
- +0.38%
- -3.89%
- 1Y return
- +4.15%
- +30.43%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 3
- 1
- Recent ratings
- 0
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest IPEX
- SEC Form DEF 14A filed by Inflection Point Acquisition Corp. V
- SEC Form 425 filed by Inflection Point Acquisition Corp. V
- Inflection Point Acquisition Corp. V filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form PRE 14A filed by Inflection Point Acquisition Corp. V
- GOWell Technology Limited and Inflection Point Acquisition Corp. V Announce Public Filing of Amendment No. 1 to the Registration Statement on Form F-4 in Connection with Proposed Business Combination
- Amendment: SEC Form SCHEDULE 13G/A filed by Inflection Point Acquisition Corp. V
- SEC Form 425 filed by Inflection Point Acquisition Corp. V
- Inflection Point Acquisition Corp. V filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 425 filed by Inflection Point Acquisition Corp. V
- Inflection Point Acquisition Corp. V filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
Latest NVS
- SEC Form 6-K filed by Novartis AG
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG